Quantcast

Latest Naloxone Stories

2014-07-23 08:31:41

LONDON, July 23, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND") with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA"), part...

2014-07-22 08:31:15

RALEIGH, N.C., July 22, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO Mr. Bramlage is a veteran pharmaceutical industry executive with extensive experience in marketing, sales and other commercial functions. He is currently the Chief Executive Officer of...

2014-07-11 23:04:58

Harbor Village Florida comments how citizens of New Jersey are receiving training on how to administer opiate-overdose reversal drug Narcan. Ocean County, NJ (PRWEB) July 11, 2014 As reported by the Star Ledger in the article Officials To Give Out 100 Free Narcan Kits in Ocean County (7/3), 100 residents of Ocean County in New Jersey recently received free training on how to administer the drug Narcan, an opiate-overdose reversal drug as well as a free kit during this previous Fourth of...

2014-07-10 08:27:14

First and only FDA approved naloxone product specifically indicated for emergency therapy in settings where opioids may be present. RICHMOND, Va., July 10, 2014 /PRNewswire/ -- Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO is not a...

2014-07-09 08:28:33

LONDON, July 9, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed an agreement with a commercial contract manufacturer to commence production of its naloxone-based opioid overdose reversal treatment. Lightlake expects that this manufacturer will be able to provide sufficient manufacturing capacity at cGMP production...

2014-06-11 12:26:03

President and CEO Mark A. Sirgo Describes BUNAVAIL(TM) Delivery, Competitive Advantages, Market Size and Patient Need RALEIGH, N.C., June 11, 2014 /PRNewswire/ -- Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) was interviewed on Bloomberg TV, TheStreet.com and Business News Network on June 11 regarding BUNAVAIL, BDSI's product for the maintenance treatment of opioid dependence that recently received approval from...

2014-06-10 08:29:27

RALEIGH, N.C., June 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at two important upcoming healthcare conferences: 34(th) Annual William Blair Growth Stock ConferenceWednesday, June 11, 20143:20 PM Central Time (4:20 PM Eastern Time)Four Seasons Hotel, Chicago, IL Wells Fargo 2014 Healthcare ConferenceTuesday, June 17, 20144:40 PM Eastern...

2014-06-06 23:01:17

A nasal-spray version of Naloxone, a heroin/opiate overdose-reversal drug, is in the works in Kentucky. (PRWEB) June 06, 2014 As reported by USA Today in the article Nasal Spray For Heroin Antidote Under Development(5/31), a Kentucky doctor has been successful in advocating a nasal spray medicine to reverse a heroin or opiate overdose. Dr. Daniel Wermeling has made a deal with a pharmaceutical company to create a nasal spray version of naloxone, a common medicine used on persons who are...

2014-06-06 16:24:14

First and Only FDA-Approved Buccal Film Formulation of Buprenorphine and Naloxone to Compete in the $1.7 Billion and Growing U.S. Opioid Dependence Market RALEIGH, N.C., June 6, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) received approval of the New Drug Application (NDA) for BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). BUNAVAIL is indicated for the maintenance treatment of...

2014-05-19 08:28:11

RICHMOND, Va., May 19, 2014 /PRNewswire/ -- Reckitt Benckiser Pharmaceuticals Inc. (RBP) announced today that it has entered into a definitive agreement with AntiOp, Inc. to co-develop a naloxone nasal spray to aid in the reversal of opioid overdose with the option to acquire all rights to the product upon receipt of regulatory and marketing approval. The product has the potential to be the first of its kind to treat overdose from opioid prescription painkillers and heroin - a growing...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related